Deerfield Management Company, L.P. (Series C) Catalyst Pharmaceuticals, Inc. Transaction History
Deerfield Management Company, L.P. (Series C)
- $5.38 Billion
- Q3 2024
A detailed history of Deerfield Management Company, L.P. (Series C) transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Deerfield Management Company, L.P. (Series C) holds 6,229,634 shares of CPRX stock, worth $128 Million. This represents 2.3% of its overall portfolio holdings.
Number of Shares
6,229,634
Previous 9,127,305
31.75%
Holding current value
$128 Million
Previous $141 Million
12.4%
% of portfolio
2.3%
Previous 2.97%
Shares
8 transactions
Others Institutions Holding CPRX
# of Institutions
326Shares Held
94.6MCall Options Held
19.1KPut Options Held
51.1K-
Black Rock Inc. New York, NY18.7MShares$385 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.04MShares$166 Million0.0% of portfolio
-
State Street Corp Boston, MA5.69MShares$117 Million0.0% of portfolio
-
Dimensional Fund Advisors LP Austin, TX3.02MShares$62.2 Million0.01% of portfolio
-
Pacer Advisors, Inc. Malvern, PA2.8MShares$57.8 Million0.13% of portfolio
About CATALYST PHARMACEUTICALS, INC.
- Ticker CPRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 102,820,000
- Market Cap $2.12B
- Description
- Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...